Znn3bq.jpeg
²é¿´: 1584  |  »Ø¸´: 8
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

mjjnj

ľ³æ (СÓÐÃûÆø)

[½»Á÷] Ò»¾ä»°ÇóÖú¸ßÈË£¡¼±°¡!£¨¹ØÓÚÁÙ´²·½ÃæµÄ£¬Ó¢Ò뺺£©

The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients¡£Sample Text

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ͨ¹ýÁÙ´²ÁÆÐ§µ÷²é,È·¶¨²¡ÈËÖеÃÒæÓÚÁÙ´²µ¼ÏòÐÔÖÎÁÆÊýÄ¿£¬¿ÉÈ·¶¨Ê×´ÎÁÆÐ§µÄ½ØÖ¹µã¡£
³ÕÃÔ¿ÆÑÐ
2Â¥2010-11-03 13:09:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

petrocatal   ÍøÓÑ·­ÒëµÃºÜºÃ£¡
3Â¥2010-11-03 13:58:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

Sample Text ¡ª¡ªÑù¶Î
4Â¥2010-11-03 13:59:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

petrocatal µÄ·­Ò뻹ÊÇûÄܰÑÒâ˼·­ÒëºÃ£¬²»¹ÜÔõÑù£¬Ö÷ÒªÁÆÐ§ÖÕµãÊÇxxxµÄÁÙ´²Ó¦´ð ÊÇÕû¸ö¾ä×ÓµÄÖ÷¸É  ÆÚ´ý¸ßÊÖ¼ÌÐø·­Ò룬лл£¡
5Â¥2010-11-03 14:05:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÁÆÐ§¡°Öյ㡱ÊÇ¡°Ó¦´ð¡±»ò·´À¡µÄ¡°·­Ò롱£¬´ÓÖÐÎÄÉϽ²¾Í²»Í¬£¬¿Ï¶¨²»ÄÜÖ±Ò룡Èç´ËÈ·¶¨¾ä×ÓµÄÖ÷¸É£¬·Ç³£±ðŤ¡£¼ò¶øÑÔÖ®£¬ÖÕµãÊÇÓ¦´ð£¿£¿
½¨Ò鏸³öÉÏÏÂÎÄ£¬Õâ¶Î»°¿Ï¶¨ÓÐÏà¹ØµÄÓï¾³£¬ÐèÒª½áºÏÉÏÏÂÎÄ£¡·­Òë¸úÄã×öÔĶÁÀí½âÒ»Ñù£¡
³ÕÃÔ¿ÆÑÐ
6Â¥2010-11-03 15:17:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (¡Ý10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7.
7Â¥2010-11-03 15:24:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɾ­ÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼Û²¡È˹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
8Â¥2010-11-03 21:22:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

mjjnj(½ð±Ò+50, ·­ÒëEPI+1):лл£¡ 2010-11-04 09:46:01
ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɽÓÊÜÁËÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼ÛµÄ²¡ÈËËù¹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
9Â¥2010-11-04 08:41:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ mjjnj µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +9 18815505510 2026-04-09 10/500 2026-04-09 11:46 by Sammy2
[¿¼ÑÐ] 286Çóµ÷¼Á +19 Faune 2026-04-08 20/1000 2026-04-09 08:36 by ŶŶ123
[¿¼ÑÐ] 320·ÖÈ˹¤ÖÇÄܵ÷¼Á +9 Õñ¡ªTZ 2026-04-03 10/500 2026-04-08 19:56 by Õñ¡ªTZ
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©×ö¹ý·Ö×ÓʵÑé +6 ÏàÐűػá¹ââÍòÕ 2026-04-07 7/350 2026-04-08 16:49 by tjzhao
[¿¼ÑÐ] Çóµ÷¼Á +14 ÕÅzic 2026-04-05 15/750 2026-04-08 16:14 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 266Çóµ÷¼Á +18 ÑôÑôÍÛÈû 2026-04-07 18/900 2026-04-08 12:59 by grayjzr
[¿¼ÑÐ] 277¡¢Ñ§Ë¶£¬Çóµ÷¼Á ÊýÒ»104£¬ +11 Æ¿×ÓPZ 2026-04-07 12/600 2026-04-07 23:30 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 313Çóµ÷¼Á +3 Ê®Áùʰ½ 2026-04-07 3/150 2026-04-07 23:20 by lbsjt
[¿¼ÑÐ] ±¾¿ÆÉúÎïÐÅϢѧ£¬×Ü·Ö362 Çó07 08µ÷¼Á +6 qСٻ1210 2026-04-06 6/300 2026-04-07 19:40 by macy2011
[¿¼ÑÐ] ר˶085403£¬291·Ö£¬ÓÐÁ½Æª×¨Àû£¬Ò»¹úÒ»½± +3 ¹þ¼ªßä¹þ¼ªßä 2026-04-07 3/150 2026-04-07 18:21 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 081700ѧ˶£¬323·Ö£¬Ò»Ö¾Ô¸Öйúº£Ñó´óѧÇóµ÷¼ÁѧУ +19 ÅûÐÇºÓ 2026-04-04 19/950 2026-04-07 15:00 by Éϰ¶¿ì¿ì
[¿¼ÑÐ] 333Çóµ÷¼Á +6 ºÏ³ËÑîϰϦ 2026-04-06 6/300 2026-04-07 09:44 by Öí»á·É
[¿¼ÑÐ] ¹¤¿Æ 22408 267ÇóÍÆ¼ö +4 wanwan00 2026-04-05 5/250 2026-04-06 22:47 by chenzhimin
[¿¼ÑÐ] 338Çóµ÷¼Á +4 ÎÒÏëÉϰ¶ii 2026-04-05 4/200 2026-04-06 21:04 by ľ×Ó¾ý1218
[¿¼ÑÐ] 308Çóµ÷¼Á +3 ÖÕ²»ËÆ´Óǰ 2026-04-05 3/150 2026-04-05 22:23 by hemengdong
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ083200 +4 whatÕÅ 2026-04-04 5/250 2026-04-05 14:07 by chw1980_0
[¿¼ÑÐ] 083200 333Çóµ÷¼Á +3 Ê®¶þ£¡£¡ 2026-04-04 3/150 2026-04-05 08:28 by barlinike
[¿¼ÑÐ] ÄÐÉú£¬Ò»Ö¾Ô¸»¦9ÉúÎïѧ071000£¬³õÊÔ308Çóµ÷¼Á +3 Áõīī 2026-04-04 3/150 2026-04-05 08:26 by barlinike
[¿¼ÑÐ] 372·Ö²ÄÁÏÓ뻯¹¤£¨085600£©Ò»Ö¾Ô¸ºþÄÏ´óѧÇóµ÷¼Á +3 À¶¼ãƬ 2026-04-03 4/200 2026-04-03 17:58 by Jimmyandyou
[¿¼ÑÐ] 302Çóµ÷¼Á +9 zyxÉϰ¶£¡ 2026-04-02 9/450 2026-04-02 23:07 by Âí¶ù¿ì¿ìµØÅÜ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û